Politics World hails U.S. reversal on vaccine patents, but hurdles persist for countries in crisis
Vaccines aplenty but some Californians struggle to get one
SAN FRANCISCO (AP) — Hearing of excess vaccine and unfilled appointments frustrates Dr. Aaron Roland, a family physician who has been lobbying for doses to inoculate his patients, many of whom are low-income, immigrants or elderly. The San Francisco Bay Area doctor has more than 200 patients who have inquired when he will offer inoculations against the coronavirus. One patient, who is 67, said he walked into a Safeway supermarket because signs said doses were available.
The Biden administration's decision towas hailed by activists and health officials Thursday as a decisive move that could upend the cozy relationship between rich countries and pharmaceutical giants and mark a crucial step toward addressing .
However, the move drew strong criticism from leading drugmakers and some experts, who are skeptical about its impact on the world's efforts to fight back against.
And the dramatic shift from Washington also raised questions about what comes next, with focus turning to whether others will follow the United States' lead.
Firefly lottery, vaccine exemptions, data breach: News from around our 50 states
How the COVID-19 pandemic is affecting every stateStart the day smarter. Get all the news you need in your inbox each morning.
Download thefor full coverage of the coronavirus outbreak
For months, the U.S. has been part of a group of rich countries that have resisted proposals by India and South Africa to relax some World Trade Organization protections related to the coronavirus vaccines.
On Wednesday, the Biden administration effectively crossed this divide between, reversing the course set by former President Donald Trump.
The historic move suggests that pharmaceutical giants may have to share their vaccine know-how and allow third-party international manufacturers to start pumping out shots for use in poorer countries.
"These extraordinary times and circumstances call for extraordinary measures," said U.S. Trade Representative Katherine Tai.
Russia lags behind others in its COVID-19 vaccination drive
MOSCOW (AP) — While at the Park House shopping mall in northern Moscow, Vladimir Makarov saw it was offering the coronavirus vaccine to customers, so he asked how long it would take. “It turned out it’s simple here — 10 minutes,” he said of his experience last month. But Makarov, like many Muscovites, still decided to put off getting the Sputnik V shot. Russia boasted last year of being first in the world to authorize a coronavirus vaccine, but it now finds itself lagging in getting its population immunized.
The debate has been thrown into sharp relief by, where mass deaths, failing oxygen supplies, and overwhelmed hospitals and crematoriums are compounded by the fact that only 2 percent of the people have been vaccinated, compared with 30 percent in the U.S.
Washington came under growing pressure on the issue in recent weeks from more than 100 low-and-middle-income countries, as well as a cavalcade of American and European lawmakers, Nobel laureates, former world leaders, human rights organizations and Pope Francis.
"The devastation wreaked by the pandemic is unprecedented and it's heartening to see the U.S. government signal that it'll put people's lives and rights first," Aruna Kashyap, an India-based lawyer with the watchdog Human Rights Watch, said.
The debate centers around something called the agreement on Trade-Related Aspects of Intellectual Property Rights — or TRIPS agreement — which governs how countries deal with each other on the issue.
EU willing to discuss waiving vaccine patents
The bloc says it is open to talks after the US backed a plan to boost Covid vaccine production.It marked a shift in position from the EU, which has previously opposed the waiver. But some member states went further, with France's president among those to give it their full support.
One immediate issue is that any decision to waive parts of this agreement at the WTO has to be made by consensus, meaning the U.S. needs other wealthy nations to back its move.
Within hours of Washington's reversal, Australia switched from blocking to supporting the TRIPS waiver. And European Union President Ursula von der Leyen said Thursday she was "ready to assess how the U.S. proposal could help" to vaccinate the world.
"In the short run, however, we call upon all vaccine producing countries to allow exports and to," she added.
The other holdouts — the United Kingdom, Japan and Brazil — have not said whether they will switch sides.
By crossing the floor from the global north to the global south, advocates say the U.S. has put itself "on the right side of history," as the charity Doctors Without Borders put it Wednesday.
World Health Organization Director-General Tedros Adhanom Ghebreyesus called Biden's move a "monumental moment in the fight against Covid-19."
Skeptics of this plan argue that the limiting factor on vaccine production isn't a lack of knowledge, but rather.
Germany is not happy with Biden's support for waiving COVID-19 vaccine patents, predicting 'severe complications'
Joe Biden's announcement in support of waiving COVID-19 vaccine patents has raised eyebrows in other nations with powerful pharmaceutical industries.A spokesperson for the German government said waiving patents would cause "severe complications" for vaccine production in an emailed statement to Bloomberg.
Even armed with the vaccine recipe, manufacturers would still be faced with shortages of syringes, vials and nanoparticles needed to make them, they say.
"I doubt whether it will make any difference whatsoever," said Sir Robin Jacob, chair of intellectual property law at University College London. He called the TRIPS campaign "a largely emotional reaction to an incredibly complex problem."
Opponents also say that forcing drugmakers to share their knowledge would mean companies would have less incentive to make lifesaving drugs in the future. Pfizer said this week that it expected to earn $26 billion this year from its Covid-19 vaccine sales alone.
"This short-sighted and ineffectual decision by the Biden administration puts the hard-won progress in fighting this terrible disease in jeopardy," said a statement from Nathalie Moll, director-general of the European Federation of Pharmaceutical Industries and Associations.
The federation is a powerful lobbying group whose board is made up of senior figures from the world's top drugmakers, such as Pfizer and AstraZeneca.
"While we wholeheartedly agree with the goal of protecting citizens around the world through vaccines," Moll said, "waiving patents will make winning the fight against the coronavirus even harder."
NHL's COVID protocol-related absences for May 7, 2021
Players in the COVID protocol are: Colorado's Devan Dubnyk and Washington's Evgeny Kuznetsov.Anaheim – TBA
The Office of the U.S. Trade Representative said that the waiver is just one part of its strategy, and that it's also trying to ramp up manufacturing not just of vaccines but of raw materials too. Amb. Tai said in her statement Wednesday that negotiations at the WTO "will take time given the consensus based nature of the institution and the complexity of the issues involved.
It's not just multibillion-dollar drugmakers that are skeptical.
— who has poured mountains of cash into getting medicines to poorer countries — told Sky News last month that he opposes relaxing intellectual property rules for the same reasons. Sky News is owned by Comcast, the parent company of NBC News.
French President Emmanuel Macron said Thursday that while he did "completely favor this opening up of the intellectual property," he harbored doubts about how this principle would work in practice, The Associated Press reported.
Advocates say drugmakers have a moral obligation to share because their shots have often been developed with billions of dollars in public money. Pfizer made a point of not accepting any public cash, but BioNTech, its partner, did get funding from the E.U. and the German government.
Even supporters know that getting poorer countries more doses and accelerating the end of the pandemic won't be easy.
They say that the waiver is just one piece of a puzzle that also needs to include rich countries snapping up fewer vaccines and donating the ones they have bought, and drugmakers entering into more voluntary agreements for others to produce their vaccines.
"We need a multipronged approach," said Siva Thambisetty, an associate professor of law at the London School of Economics.
"The IP waiver is a masthead — a lot of different kinds of actions now need to flow."
Giving away the COVID vaccine formula helps no one and harms America .
In the long run, the United States must lead on COVID-19 vaccination and recovery efforts. This includes widespread vaccine distribution, developing advanced approaches to manage COVID-19-related chronic conditions that may arise in recovered adults, and advancing the process for receiving necessary boosters.